Senti Biosciences (SNTI) Set to Announce Quarterly Earnings on Thursday

Senti Biosciences (NASDAQ:SNTI) is anticipated to release its Q3 2026 results before the market opens on Thursday, November 12th. Analysts expect Senti Biosciences to announce earnings of ($0.21) per share and revenue of $0.02 million for the quarter. Parties can find conference call details on the company’s upcoming Q3 2026 earnings report page for the latest details on the call scheduled for Friday, November 20, 2026 at 4:00 PM ET.

Senti Biosciences (NASDAQ:SNTI) last posted its earnings results on Friday, August 14th. The company reported ($0.41) EPS for the quarter, missing analysts’ consensus estimates of ($0.33) by ($0.08). The company had revenue of $0.02 million for the quarter. On average, analysts expect Senti Biosciences to post ($1.53) EPS for the current fiscal year and ($0.94) EPS for the next fiscal year.

Senti Biosciences Stock Performance

Shares of SNTI opened at $0.16 on Tuesday. Senti Biosciences has a twelve month low of $0.15 and a twelve month high of $2.88. The company has a 50 day moving average of $0.27 and a two-hundred day moving average of $0.70.

Analysts Set New Price Targets

Separately, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Senti Biosciences in a research report on Thursday, October 15th. One equities research analyst has rated the stock with a Strong Buy rating, one has given a Buy rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $9.00.

About Senti Biosciences

Senti Biosciences, Inc is a biotechnology company developing gene and cell therapies for cancer and other serious diseases. The company’s technology is based on synthetic biology, including programmable gene circuits designed to help engineered immune cells recognize disease-associated targets, respond to specific biological signals and limit activity in healthy tissue.

Senti Biosciences applies its platform to the development of engineered cell therapies, including chimeric antigen receptor natural killer (CAR-NK) and other immune-cell programs.